Full Breakdown
FDA Grants First-in-Class Approval to Celcuity’s Revtorpyk for Advanced Breast Cancer
7/16/2026, 9:10:12 PM
Core Event
On July 15, 2026, the U.S. Food and Drug Administration approved gedatolisib—marketed as Revtorpyk—for adults with hormone-receptor-positive, HER2-negative breast cancer that is locally advanced or metastatic and lacks a PIK3CA mutation. The drug is authorized as a second-line therapy and will be administered as a 30-minute intravenous infusion on days 1, 8 and 15 of a 28-day cycle, in combination with AstraZeneca’s Faslodex and, optionally, Pfizer’s Ibrance.
Background & Context
HR-positive, HER2-negative disease represents roughly 70 % of breast cancers, and about 60 % of these lack PIK3CA mutations. Celcuity, based in Minneapolis, designed Revtorpyk to inhibit both PI3K and mTOR components of the PAM (PI3K-AKT-mTOR) signaling pathway, thereby also suppressing downstream AKT activity. Existing therapies target either PI3K or mTOR alone; Revtorpyk’s dual mechanism aims to improve progression-free survival, which the open-label Phase 3 trial demonstrated as statistically significant, though overall-survival data remain immature.
Official Statements & Responses
Celcuity announced that the launch will occur late in the third quarter of 2026 to ensure adequate drug supply. The company indicated that pricing details are being finalized but that it has already engaged the nation’s top payers to facilitate insurance coverage. In a conference call, executives emphasized the importance of managing mucositis to maintain patient adherence.
Criticism & Opposition
Analyst Andrew Berens of Leerink Partners highlighted a 12 % discontinuation rate for the triple-drug regimen, attributing the figure primarily to mucosal inflammation. He warned that community physicians’ ability to control this side effect will be pivotal for commercial success.
Verbatim Quotes
- “Once the drug launches, we think the ability of community docs to effectively manage the mucositis and keep patients on drug will be critical to commercial success,” — Andrew Berens, Leerink Partners analyst
- “In a note sent to investors Wednesday, Leerink Partners analyst Andrew Berens said the 12% discontinuation rate for the triple combination was higher than expected, driven in large part by the mucus membrane adverse effect.” — Andrew Berens, Leerink Partners analyst
